<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29961">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01723917</url>
  </required_header>
  <id_info>
    <org_study_id>AG033288</org_study_id>
    <secondary_id>R01AG033288</secondary_id>
    <nct_id>NCT01723917</nct_id>
  </id_info>
  <brief_title>Phytoserms for Menopause Symptoms and Age-Associated Memory Decline</brief_title>
  <acronym>phytoSERM</acronym>
  <official_title>Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age-Associated Memory Decline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of a soy based dietary
      supplement (phytoSERM) for hot flashes and age associated memory loss.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>as measured by assessment of AEs, co-morbid events, laboratory measures, symptoms and cognitive performance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change from baseline in neuropsychological (cognitive, functional) test results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change from baseline in vasomotor symptoms</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Hot Flashes</condition>
  <condition>Memory Loss</condition>
  <arm_group>
    <arm_group_label>PhytoSERM 50 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PhytoSERM 100 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary supplement: PhytoSERM tablet to be taken once per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary supplement: placebo tablet to be taken once per day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PhytoSERM tablet</intervention_name>
    <arm_group_label>PhytoSERM 50 mg tablet</arm_group_label>
    <arm_group_label>PhytoSERM 100 mg tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  post-menopausal women

          -  ages 48 - 58 (inclusive)

          -  must have a vasomotor symptom (e.g., hot flash) and a memory complaint

        Exclusion Criteria:

          -  history of clinically significant stroke

          -  current evidence or history in past 2 years of epilepsy, seizure, focal brain lesion,
             head injury with loss of consciousness or any major psychiatric disorder including
             psychosis, major depression, bipolar disorder, alcohol or substance abuse

          -  Known allergy to soy derived products; hypersensitivity to estrogens or
             progestins
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>48 Years</minimum_age>
    <maximum_age>58 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lon S Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerson Hernandez, MD</last_name>
      <phone>323-442-5775</phone>
      <email>gersonhe@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nadine Diaz, MSW</last_name>
      <phone>(323) 442-5775</phone>
      <email>ndiaz@usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lon Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 7, 2012</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amnesia</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
